IL-1B polymorphism in association with initial intravenous immunoglobulin treatment failure in Taiwanese children with Kawasaki disease.
BACKGROUND
Approximately 8-38% of children with Kawasaki disease (KD) will have persistent or recrudescent fever after initial intravenous immunoglobulin (IVIG) treatment and are at increased risk for development of coronary artery abnormalities. Using genetic markers may be helpful to identify the high-risk group of IVIG-resistant patients for aggressive treatment. The aim of this study was to evaluate the associations between 4 potential polymorphisms in the interleukin (IL)-1 family of genes and initial IVIG treatment failure in KD children.


RESULTS
A total of 156 KD children (136 with and 20 without a response to IVIG treatment) who were treated with high-dose IVIG (2 g/kg) within 10 days of fever onset were recruited. Polymerase chain reaction and Taqman assays were used for genotyping. A significant increase in IVIG resistance risk was observed for IL-1B -511 TT and IL-1B -31 CC genotypes (adjusted odds ratio (AOR) 5.27, 95% confidence interval (CI) 1.69-16.38, P=0.004; AOR 3.95, 95%CI 1.26-12.41, P=0.019, separately). The diplotype TC/TC (at IL-1B -511 and -31) also showed a significantly increased risk of IVIG resistance (AOR 4.32, 95%CI 1.36-13.71, P=0.013).


CONCLUSIONS
The IL-1B -511 TT and IL-1B -31 CC genotypes or the TC/TC diplotype may be associated with initial IVIG treatment failure in Taiwanese children with KD.
Weng
Ken-Pen
KP
Department of Pediatrics, Kaohsiung Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan, ROC.
Hsieh
Kai-Sheng
KS
Ho
Tsyr-Yuh
TY
Huang
Shih-Hui
SH
Lai
Chung-Ren
CR
Chiu
Yi-Ten
YT
Huang
Shih-Chen
SC
Lin
Chu-Chuan
CC
Hwang
Yu-Tung
YT
Ger
Luo-Ping
LP
D002675:Child, Preschool; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D015994:Incidence; D007223:Infant; D053583:Interleukin-1beta / Q000235:genetics*; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000453:epidemiology / Q000276:immunology* / Q000628:therapy*; D012189:Retrospective Studies; D012307:Risk Factors; D013624:Taiwan / Q000453:epidemiology; D017211:Treatment Failure
D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D053583:Interleukin-1beta